Rein Therapeutics, Inc.
RNTX
Positions held
Your positionsRNTX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $66.37M | Enterprise value | $70.72M | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | 6.46 | Beta | 1.36 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -96.4% | ROA | -21.0% | Debt / equity | — |
| Current ratio | 4.27 | Free cash flow | -$7.79M | Analyst recommendation | none | Mean target | $6.00 |
| 52w high | $2.18 | 52w low | $0.69 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$6.4M | -$5.8M | -$32.0M | -$5.6M | -$6.8M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$6.1M | -$5.2M | -$4.0M | -$5.5M | -$6.9M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$49.9M | -$62.9M | -$15.7M | -$27.3M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$21.9M | -$28.1M | -$15.3M | -$27.6M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-04 · Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
2026-09-03 · Rein Therapeutics to Present at Upcoming September Investor Conferences
2026-09-03 · Here's Why You Should Add RNTX Stock to Your Portfolio Now
2026-08-20 · Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
2026-08-14 · Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
2026-08-04 · Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
2026-07-21 · Rein Therapeutics Completes Global Expansion of Phase 2 IPF Trial
2026-07-21 · Rein Therapeutics Announces Phase 2 RENEW Trial Now Enrolling Across All Five Countries
Price (daily)
Full chart · RSI · MACD · patterns